CHICAGO, ILLINOIS --- JUNE 19, 2017 --- Firma Clinical Research, an ISO quality management-certified clinical research organization (CRO), announced its launch and official unveiling at the Drug Information Association (DIA) 2017 Conference in Chicago, Illinois, June 18-22, 2017. The new company combines the expertise of Pharma Start and H20 Clinical, two clinical service organizations previously working in close collaboration, following an investment with management by Thompson Street Capital Partners, a St. Louis-based private equity firm. Built on decades of clinical development leadership and expertise, Firma Clinical supports the drug development efforts of pharmaceutical and biotech companies through advanced in-home patient visits, data management & biostatistics, medical writing, regulatory consulting, clinical pharmacology, and clinical operations. The executive team at Firma Clinical is led by:
The newly-formed Board of Directors consists of Chairman, Stephen Sullivan, Founder, CRO Advisors, LLC, Matt Scherrer, Managing Director, Thompson Street Capital Partners, Eugenia Henry, Chrissy Fleming, and Earl Henry. “We’re passionate about providing our clients with the highest-quality experience for every project we take on,” said Fleming. “We’re excited to apply that passion, knowledge, and flexibility by working side-by-side with our clients as partners to advance medicine and treatments to improve human lives.” “Our new brand and singular organization structure formalizes our unique approach to solving challenges and serving our clients in clinical development. This corporate transformation is the reflection of the collaboration and support that inspires our team to continue advancing the development of work with our clients on all of our projects,” Eugenia Henry added. Firma will be exhibiting at DIA in booth #1548. Contact us to schedule a time to meet with a team member and learn how our support can facilitate your team in making informed decisions that lead to better development outcomes. For additional information, please call 888.330.1726 or contact us at info@firmaclinical.com.
About Firma Clinical Research
An ISO 9001:2015 quality-certified organization, Firma Clinical provides focused CRO services enabling pharmaceutical and biotech clients to plan for and advance research in the drug development landscape. This support enables clients to make informed decisions that lead to better outcomes. Firma is dedicated to a collaborative approach that accelerates the development of safe and effective treatments for the pharmaceutical, biotechnology, and medical device industries. The company offers a wide array of tailored processes and services across all phases of clinical development, strategically focusing on flexible solutions, transparent communication, and on-time deliverables. For more information, please visit www.firmaclinical.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.